COVID-19-Related Stroke

Hess, David C.; Eldahshan, Wael; Rutkowski, Elizabeth

doi:10.1007/s12975-020-00818-9

Cited by 359 publications

(388 citation statements)

References 25 publications

Supporting

Mentioning

342

Contrasting

Unclassified

Order By: Relevance

“…While the role of anticoagulation, like LMWH, in this clinical context is still unclear. [57] Harzallah et al recommended early anticoagulation therapy for individuals with COVID-19 infection and positive lupus anticoagulant. [58] Previous investigations suggested that COVID-19 is associated with both platelet and clotting cascade activation.…”

Section: Discussionmentioning

confidence: 99%

Neurological Involvement of Coronavirus Disease 2019: A Systematic Review

Ghannam

Alshaer

Al-Chalabi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: In December 2019, unexplained cases of pneumonia emerged in Wuhan, China, which were found to be secondary to the novel coronavirus SARS-CoV-2. On March 11, 2020, the WHO declared the Coronavirus Disease 2019 (COVID-2019) outbreak, a pandemic. Although the most common presentations of COVID-19 are fever, cough and shortness of breath, several clinical observations indicate that COVID-19 does affect the central and peripheral nervous system. Methods: We conducted a systematic literature search from December 01, 2019 to May 14, 2020 using multiple combinations of keywords from PubMed and Ovid Medline databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included articles with cases of COVID-19 that were evident for neurological involvement. Results: We were able to identify 82 cases of COVID-19 with neurological complications. The mean age was 62.28 years. 37.8% of the patients were women (n = 31). 48.8% of the patients (n=40) had cerebrovascular insults, 28% (n=23) had neuromuscular disorders, 18.3% of the patients (n=15) had encephalitis or encephalopathy, and 2.4% (n=2) presented with status epilepticus. Conclusions: Neurological manifestations of COVID-19 infection are not rare, especially large vessel stroke, Guillain barre syndrome and meningoencephalitis. Moving forward, further studies are needed to clarify the prevalence of the neurological complications of COVID-19, investigate their biological backgrounds, and test treatment options. Physicians should be cautious not to overlook other neurological diagnoses that can mimic COVID-19 during the pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Neurological Involvement of Coronavirus Disease 2019: A Systematic Review

Ghannam

Alshaer

Al-Chalabi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Coagulopathy induced by severe COVID-19 may lead to stroke [2]. Most reported cases present with respiratory symptoms initially, followed by stroke several days later [2,3]. However, we present a case of asymptomatic COVID-19 in an 84-year-old woman, who presented with stroke.…”

Section: Introductionmentioning

confidence: 84%

“…The unique feature of our case was that stroke occurred before the presentation of any other symptoms of COVID-19. According to the literature, coagulopathy occurs as a severe complication of COVID-19 [1,2,3]. However, in the study of Fara et al, coagulopathy may occur even in mild cases [6].…”

Section: Case Reportmentioning

confidence: 99%

“…The cause is unclear. However, coagulopathy with high D-dimer levels and endothelial dysfunction induced by COVID-19 have been considered to be associated with stroke [1,2,3]. In most cases, cerebral vascular disease occurs several days after the onset of COVID-19 [4,5].…”

Section: Case Reportmentioning

confidence: 99%

“…Although, COVID-19 most commonly manifests as a respiratory syndrome, severe COVID-19 may also present with coagulopathy, leading to venous thrombosis and cerebral infarction [1]. Coagulopathy induced by severe COVID-19 may lead to stroke [2]. Most reported cases present with respiratory symptoms initially, followed by stroke several days later [2,3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

D-dimer level elevation can aid in detection of asymptomatic COVID-19 presenting with acute cerebral infarction

Umemura¹,

Kondo²,

Ohta³

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) mainly manifests as a respiratory syndrome, besides causing other complications. Severe COVID-19 may also present with coagulopathy, leading to venous thrombosis and cerebral infarction. Stroke is one of the complications associated with severe COVID-19. Generally, acute stroke is the second complication in patients with respiratory syndrome. Here, we present a case of COVID-19 in an 84-year-old female patient who did not manifest any respiratory symptoms; however, she presented with acute stroke. The patient had no cough or fever before the stroke onset, but the COVID-19 PCR was positive. The patient also had markedly elevated D-dimer levels. Our findings suggest that coagulopathy can occur, even in a patient with asymptomatic COVID-19 infection. To our knowledge, this is the first case of asymptomatic COVID-19 in a patient presenting with cerebral infarction. We concluded that elevation of D-dimer levels is one of the tools to ascertain COVID-19 infection in such patients.

show abstract

The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning

Erausquin

Snyder

Carrillo

et al. 2021

Alzheimer's & Dementia

173

154

View full text Add to dashboard Cite

Introduction:The increasing evidence of SARS-CoV-2 impact on the central nervous system (CNS) raises key questions on its impact for risk of later life cognitive decline, Alzheimer's disease (AD), and other dementia.Methods: The Alzheimer's Association and representatives from more than 30 countries-with technical guidance from the World Health Organization-have formed an international consortium to study the short-and long-term consequences of SARS-CoV-2 on the CNS-including the underlying biology that may contribute to AD and other dementias. This consortium will link teams from around the world covering more than 22 million COVID-19 cases to enroll two groups of individuals including people with disease, to be evaluated for follow-up evaluations at 6, 9, and 18 months, and people who are already enrolled in existing international research studies to add additional measures and markers of their underlying biology. Conclusions:The increasing evidence and understanding of SARS-CoV-2's impact on the CNS raises key questions on the impact for risk of later life cognitive decline, AD, and other dementia. This program of studies aims to better understand the long-term consequences that may impact the brain, cognition, and functioning-including the underlying biology that may contribute to AD and other dementias.

show abstract

COVID-19-Related Stroke

Cited by 359 publications

References 25 publications

Neurological Involvement of Coronavirus Disease 2019: A Systematic Review

Neurological Involvement of Coronavirus Disease 2019: A Systematic Review

D-dimer level elevation can aid in detection of asymptomatic COVID-19 presenting with acute cerebral infarction

The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning

Contact Info

Product

Resources

About